L-DOPA Improves Ventilation but Not the Ventilatory Response to Hypercapnia in a Reserpine Model of Parkinson's Disease
- PMID: 37239247
- PMCID: PMC10216042
- DOI: 10.3390/brainsci13050775
L-DOPA Improves Ventilation but Not the Ventilatory Response to Hypercapnia in a Reserpine Model of Parkinson's Disease
Abstract
Parkinson's disease (PD) is a neurological disorder characterized by progressive degeneration of the substantia nigra that affects mainly movement control. However, pathological changes associated with the development of PD may also alter respiration and can lead to chronic episodes of hypoxia and hypercapnia. The mechanism behind impaired ventilation in PD is unclear. Therefore, in this study, we explore the hypercapnic ventilatory response in a reproducible reserpine-induced (RES) model of PD and parkinsonism. We also investigated how dopamine supplementation with L-DOPA, a classic drug used to treat PD, would affect the breathing and respiratory response to hypercapnia. Reserpine treatment resulted in decreased normocapnic ventilation and behavioral changes manifested as low physical activity and exploratory behavior. The respiratory rate and the minute ventilation response to hypercapnia were significantly higher in sham rats compared to the RES group, while the tidal volume response was lower. All of this appears to be due to reduced baseline ventilation values produced by reserpine. L-DOPA reversed reduced ventilation, indicating a stimulatory effect of DA on breathing, and showed the potency of DA supplementation in restoring normal respiratory activity.
Keywords: L-DOPA; Parkinson’s disease; breathing; hypercapnia; rat model; reserpine.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Effect of 6-OHDA on hypercapnic ventilatory response in the rat model of Parkinson's disease.Physiol Res. 2019 Apr 30;68(2):285-293. doi: 10.33549/physiolres.933949. Epub 2019 Jan 10. Physiol Res. 2019. PMID: 30628829
-
Respiratory deficits in a female rat model of Parkinson's disease.Exp Physiol. 2022 Nov;107(11):1349-1359. doi: 10.1113/EP090378. Epub 2022 Sep 8. Exp Physiol. 2022. PMID: 36030407
-
Respiratory deficits in a rat model of Parkinson's disease.Neuroscience. 2015 Jun 25;297:194-204. doi: 10.1016/j.neuroscience.2015.03.048. Epub 2015 Mar 30. Neuroscience. 2015. PMID: 25838118
-
The medical treatment of Parkinson disease from James Parkinson to George Cotzias.Mov Disord. 2015 Jan;30(1):4-18. doi: 10.1002/mds.26102. Epub 2014 Dec 9. Mov Disord. 2015. PMID: 25491387 Review.
-
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8. Mov Disord. 2015. PMID: 25488030 Review.
References
-
- Triarhou L.C. Introduction. Dopamine and Parkinson’s disease. Adv. Exp. Med. Biol. 2002;517:1–14. - PubMed
LinkOut - more resources
Full Text Sources